Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s disease.

The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active Crohn’s disease.

These results are among the 14 Johnson & Johnson abstracts presented at the American College of Gastroenterology 2024.

Also Read: Johnson & Johnson’s Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body’s Smaller Areas.

GRAVITI  Subcutaneous Induction Week 12 Results:

More than half of patients treated with Tremfya (400 mg administered subcutaneously at Weeks 0, 4, and 8) ...